Form D · Venture Capital Fund

Redmile Biopharma Investments III, L.P.

San Francisco, CA · CIK 0001838746

Offering snapshot reported Jan 4, 2021 · SEC filing

Reported sold: $500M
Investors reported: 77
Minimum accepted: $100K
First sale: Dec 23, 2020

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jan 4, 2021	Initial	$500,235,000	No comparison	77	SEC filing

Offering details

Securities: Pooled investment fund
Exemptions: 06b, 3C, 3C.7
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-385117

Sales compensation recipients

Scroll to see all columns →

Recipient	CRD	Associated broker-dealer
J.P. Morgan Securities LLC	79

Source: Form D, filed Jan 4, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

The linked fund shows its most recently reported ADV details.

Matched by reported Form D file number

REDMILE BIOPHARMA INVESTMENTS III, L.P.

Investment adviser: REDMILE GROUP, LLC

Gross asset value: $1.13B
Beneficial owners: 330
ADV minimum commitment: $5M

Reported in Form ADV on Aug 28, 2026. Fund assets and beneficial owners measure different things from Form D sales and investors.

Service providers

Fund administrator ALTER DOMUS (US) LLC CHICAGO, Illinois, United States Investor statements: Yes (provided to all investors) Related to adviser: No

Auditor ERNST & YOUNG LLP SAN FRANCISCO, California, United States

Custodian JP MORGAN CHASE BANK, N.A. NEW YORK, New York, United States Related to adviser: No

Custodian MORGAN STANLEY & CO. LLC SAN FRANCISCO, California, United States Related to adviser: No

Marketer J.P. MORGAN SECURITIES LLC NEW YORK, New York, United States Related to adviser: No

Prime broker MORGAN STANLEY & CO. LLC SAN FRANCISCO, California, United States

Provider details

Annual audit: Yes
Prime brokers: Yes
Custodians: Yes
Administrator other than the adviser: Yes
External marketing: Yes

ERNST & YOUNG LLP
PCAOB 42

JP MORGAN CHASE BANK, N.A.
LEI 7H6GLXDRUGQFU57RNE97

MORGAN STANLEY & CO. LLC
SEC 8-15869

J.P. MORGAN SECURITIES LLC
CRD 79 · SEC 801-3702

MORGAN STANLEY & CO. LLC
CRD 8209 · SEC 8-15869

Filing source

Form ADV 2125340 · Aug 28, 2026 · Schedule D 7.B.(1), fund 805-5445849187

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Jeremy Green	Executive
Mike Lee	Executive
Amrit Nagpal	Executive
N/A Redmile Biopharma Investments Iii (Gp), Llc	Promoter
N/A Redmile Group, Llc	Executive

Issuer details

Industry: Pooled Investment Fund (See others in industry)

Address:

Letterman Digital Arts Center One Letterman Drive, Suite D3 300
San Francisco, CA, 94129